Maria Sklodowska-Curie National Research Institute of Oncology
nio.gov.plLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
64
Active
16
Phase 3
8
Total enrollment
78,960
Pipeline matrix
Showing 9 of 9 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin 10 MG | — | — | — | — | — | 1 | |
| Lutetium (177Lu) vipivotide tetraxetan | — | — | — | — | — | 2 | |
| Cladribine | — | — | — | — | — | 1 | |
| Pembrolizumab 25 MG/ML [Keytruda] | — | — | — | — | — | 1 | |
| Obinutuzumab | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Opdivo | — | — | — | — | — | 1 | |
| Pembrolizumab, Eftilagimod alfa | — | — | — | — | — | 1 | |
| Keytruda | — | — | — | — | — | 1 |
Next readouts
- 2025-04-30
- 2025-12-31
- 2025-12-31
- 2027-05-31
- 2027-12-31
- 2028-01-01
- 2028-02-28
- 2030-11
Top conditions
- Colorectal Cancer9
- Rectal Cancer6
- Myxoid Liposarcoma3
- Multiple Myeloma2
- Cervical Cancer2
- Screening2
- Prostate Cancer2
- Sarcoma2
Frequently asked questions about Maria Sklodowska-Curie National Research Institute of Oncology
- How many clinical trials does Maria Sklodowska-Curie National Research Institute of Oncology have on ClinicalTrials.gov?
- Maria Sklodowska-Curie National Research Institute of Oncology is listed as the lead sponsor on 64 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Maria Sklodowska-Curie National Research Institute of Oncology's trials are in Phase 3?
- 8 of Maria Sklodowska-Curie National Research Institute of Oncology's trials are in Phase 3, spread across 9 active drug programs.
- What therapeutic areas does Maria Sklodowska-Curie National Research Institute of Oncology focus on?
- Maria Sklodowska-Curie National Research Institute of Oncology's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Rectal Cancer, Myxoid Liposarcoma, Multiple Myeloma, Cervical Cancer.
- When are Maria Sklodowska-Curie National Research Institute of Oncology's next clinical trial readouts?
- Maria Sklodowska-Curie National Research Institute of Oncology has 8 upcoming primary-completion readouts tracked here; the soonest is “Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial”, expected around 2025-04-30.